Kaposi’s sarcoma is the leading cause of cancer in HIV infected persons. It is caused by infection with Kaposi’s sarcoma-associated herpesvirus, which is endemic in sub-Saharan Africa. This is also the part of the world most affected by the HIV/AIDS epidemic. Out of 34 million HIV-infected individuals worldwide, 24 million (69%) live in sub-Saharan Africa. The current treatment options for Kaposi’s sarcoma are limited, and the disease is often incurable. The goal of this study is to develop and test a sub-unit vaccine with an outstanding potential to blunt Kaposi’s sarcoma-associated herpes virus infection. Successful implementation of this study will lead to an effective vaccine capable of preventing Kaposi’s sarcoma.